Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy

Colombo, GL; Valentino, MC; Fabi, A; Dieci, MV; Caruggi, M; Bruno, GM; Lombardi, G; Di Matteo, S

Colombo, GL (通讯作者)，Univ Pavia, Dept Drug Sci, Pavia, Italy.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023; 19 (): 301

Abstract

Background: To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemacicli......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索